BR112012011274A2 - formulação de metformina de massa reduzida e sua combinação - Google Patents
formulação de metformina de massa reduzida e sua combinaçãoInfo
- Publication number
- BR112012011274A2 BR112012011274A2 BR112012011274A BR112012011274A BR112012011274A2 BR 112012011274 A2 BR112012011274 A2 BR 112012011274A2 BR 112012011274 A BR112012011274 A BR 112012011274A BR 112012011274 A BR112012011274 A BR 112012011274A BR 112012011274 A2 BR112012011274 A2 BR 112012011274A2
- Authority
- BR
- Brazil
- Prior art keywords
- reduced mass
- combination
- mass metformin
- metformin formulation
- formulation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Obesity (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
formulações de metformina de massa reduzida. a presente invenção refere-se ás formulações de liberação prolongada de metformina (xr) com compactibilidade melhorada para prover comprimidos, granulações, e cápsulas de massa reduzida.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26104909P | 2009-11-13 | 2009-11-13 | |
PCT/US2010/056525 WO2011060255A1 (en) | 2009-11-13 | 2010-11-12 | Reduced mass metformin formulations |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112012011274A2 true BR112012011274A2 (pt) | 2016-04-12 |
Family
ID=43430616
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112012011274A BR112012011274A2 (pt) | 2009-11-13 | 2010-11-12 | formulação de metformina de massa reduzida e sua combinação |
Country Status (10)
Country | Link |
---|---|
US (2) | US20120294936A1 (pt) |
EP (1) | EP2498757A1 (pt) |
JP (1) | JP5798123B2 (pt) |
CN (1) | CN102711738A (pt) |
AU (1) | AU2010319438B2 (pt) |
BR (1) | BR112012011274A2 (pt) |
CA (1) | CA2780938A1 (pt) |
MX (1) | MX2012005425A (pt) |
RU (1) | RU2564901C2 (pt) |
WO (1) | WO2011060255A1 (pt) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2780939C (en) * | 2009-11-13 | 2018-06-12 | Bristol-Myers Squibb Company | Bilayer tablet formulations |
CN102440976A (zh) * | 2011-12-21 | 2012-05-09 | 南京海陵中药制药工艺技术研究有限公司 | 依帕司他缓释片及其制备方法 |
WO2014154640A1 (en) * | 2013-03-25 | 2014-10-02 | Sanovel Ilac Sanayi Ve Ticaret A.S. | Controlled-release formulations comprising metformin and gliclazide |
EP2783681A1 (en) * | 2013-03-25 | 2014-10-01 | Sanovel Ilac Sanayi ve Ticaret A.S. | Extended release formulations of metformin |
GB201312128D0 (en) * | 2013-07-05 | 2013-08-21 | Proximagen Ltd | Drug combination and its use in therapy |
CN103399112B (zh) * | 2013-07-24 | 2015-07-15 | 上海交通大学 | 一种盐酸二甲双胍含量的测定方法 |
CN103816130B (zh) * | 2014-01-22 | 2016-01-20 | 悦康药业集团有限公司 | 一种盐酸二甲双胍缓释片 |
EA023747B1 (ru) * | 2014-11-13 | 2016-07-29 | Промомед Холдингс Лимитед | Фармацевтическая композиция для профилактики и лечения нарушений, связанных с избыточным весом или ожирением (варианты), наборы (варианты), их применение и способ профилактики и лечения нарушений, связанных с избыточным весом или ожирением |
CN104324033A (zh) * | 2014-11-20 | 2015-02-04 | 哈尔滨圣吉药业股份有限公司 | 一种西格列汀二甲双胍缓释片及其制备方法 |
CN105476995A (zh) * | 2015-12-23 | 2016-04-13 | 青岛海之源智能技术有限公司 | 一种二甲双胍阿昔莫司复方缓释胶囊及制备方法 |
CN106924208A (zh) * | 2015-12-30 | 2017-07-07 | 深圳翰宇药业股份有限公司 | 一种复方达格列净二甲双胍缓释片及其制备方法 |
BR112018073688A2 (pt) * | 2016-05-20 | 2019-02-26 | Center Laboratories, Inc. | método de tratamento de hiperglicemia |
FR3053892A1 (fr) * | 2016-07-12 | 2018-01-19 | Urgo Recherche Innovation Et Developpement | Pansement permettant la liberation controlee et prolongee de la metformine |
US10639292B2 (en) | 2018-04-20 | 2020-05-05 | Center Laboratories, Inc. | Method of treating hyperglycemia |
SG11202011883RA (en) * | 2018-05-31 | 2020-12-30 | Hua Medicine Shanghai Ltd | Pharmaceutical combination, composition, and combination formulation containing glucokinase activator and ppar receptor activator, and preparation methods and uses thereof |
JP2023518645A (ja) * | 2020-01-16 | 2023-05-08 | 上海仁会生物制▲やく▼股▲ふん▼有限公司 | Glp-1の投薬レジメン |
Family Cites Families (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6005A (en) * | 1849-01-09 | Machine for hook-heading spikes by one motion | ||
US8027A (en) * | 1851-04-08 | Thomas j | ||
US3174901A (en) | 1963-01-31 | 1965-03-23 | Jan Marcel Didier Aron Samuel | Process for the oral treatment of diabetes |
US3674836A (en) | 1968-05-21 | 1972-07-04 | Parke Davis & Co | 2,2-dimethyl-{11 -aryloxy-alkanoic acids and salts and esters thereof |
US4027009A (en) | 1973-06-11 | 1977-05-31 | Merck & Co., Inc. | Compositions and methods for depressing blood serum cholesterol |
JPS5612114B2 (pt) | 1974-06-07 | 1981-03-18 | ||
US4231938A (en) | 1979-06-15 | 1980-11-04 | Merck & Co., Inc. | Hypocholesteremic fermentation products and process of preparation |
DK149080C (da) | 1980-06-06 | 1986-07-28 | Sankyo Co | Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre |
US4450171A (en) | 1980-08-05 | 1984-05-22 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
US4448784A (en) | 1982-04-12 | 1984-05-15 | Hoechst-Roussel Pharmaceuticals, Inc. | 1-(Aminoalkylphenyl and aminoalkylbenzyl)-indoles and indolines and analgesic method of use thereof |
US5354772A (en) | 1982-11-22 | 1994-10-11 | Sandoz Pharm. Corp. | Indole analogs of mevalonolactone and derivatives thereof |
US4499289A (en) | 1982-12-03 | 1985-02-12 | G. D. Searle & Co. | Octahydronapthalenes |
CA1327360C (en) | 1983-11-14 | 1994-03-01 | William F. Hoffman | Oxo-analogs of mevinolin-like antihypercholesterolemic agents |
US4613610A (en) | 1984-06-22 | 1986-09-23 | Sandoz Pharmaceuticals Corp. | Cholesterol biosynthesis inhibiting pyrazole analogs of mevalonolactone and its derivatives |
US4686237A (en) | 1984-07-24 | 1987-08-11 | Sandoz Pharmaceuticals Corp. | Erythro-(E)-7-[3'-C1-3 alkyl-1'-(3",5"-dimethylphenyl)naphth-2'-yl]-3,5-dihydroxyhept-6-enoic acids and derivatives thereof |
US4647576A (en) | 1984-09-24 | 1987-03-03 | Warner-Lambert Company | Trans-6-[2-(substitutedpyrrol-1-yl)alkyl]-pyran-2-one inhibitors of cholesterol synthesis |
HU198005B (en) | 1984-12-04 | 1989-07-28 | Sandoz Ag | Process for producing mevqlolakton, derivatives, its indene-analogues and pharmaceutical compositions containing them |
US4668794A (en) | 1985-05-22 | 1987-05-26 | Sandoz Pharm. Corp. | Intermediate imidazole acrolein analogs |
HUT48208A (en) | 1985-10-25 | 1989-05-29 | Sandoz Ag | Process for producing heterocyclic analogues of mevalolactone derivatives and pharmaceutical compositions comprising such compounds |
FR2596393B1 (fr) | 1986-04-01 | 1988-06-03 | Sanofi Sa | Derives de l'acide hydroxy-3 dihydroxyoxophosphorio-4 butanoique, leur procede de preparation, leur application comme medicament et les compositions les renfermant |
US5614492A (en) | 1986-05-05 | 1997-03-25 | The General Hospital Corporation | Insulinotropic hormone GLP-1 (7-36) and uses thereof |
US4681893A (en) | 1986-05-30 | 1987-07-21 | Warner-Lambert Company | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis |
NZ224733A (en) | 1987-05-22 | 1990-12-21 | Squibb & Sons Inc | Organophosphorus hmg-coa reductase inhibitors; intermediates and compositions thereof |
US4759923A (en) | 1987-06-25 | 1988-07-26 | Hercules Incorporated | Process for lowering serum cholesterol using poly(diallylmethylamine) derivatives |
JP2569746B2 (ja) | 1987-08-20 | 1997-01-08 | 日産化学工業株式会社 | キノリン系メバロノラクトン類 |
US4871721A (en) | 1988-01-11 | 1989-10-03 | E. R. Squibb & Sons, Inc. | Phosphorus-containing squalene synthetase inhibitors |
US4924024A (en) | 1988-01-11 | 1990-05-08 | E. R. Squibb & Sons, Inc. | Phosphorus-containing squalene synthetase inhibitors, new intermediates and method |
NO177005C (no) | 1988-01-20 | 1995-07-05 | Bayer Ag | Analogifremgangsmåte for fremstilling av substituerte pyridiner, samt mellomprodukter til bruk ved fremstillingen |
US5506219A (en) | 1988-08-29 | 1996-04-09 | E. R. Squibb & Sons, Inc. | Pyridine anchors for HMG-CoA reductase inhibitors |
US5753675A (en) | 1989-03-03 | 1998-05-19 | Novartis Pharmaceuticals Corporation | Quinoline analogs of mevalonolactone and derivatives thereof |
FI94339C (fi) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
US5177080A (en) | 1990-12-14 | 1993-01-05 | Bayer Aktiengesellschaft | Substituted pyridyl-dihydroxy-heptenoic acid and its salts |
JP2648897B2 (ja) | 1991-07-01 | 1997-09-03 | 塩野義製薬株式会社 | ピリミジン誘導体 |
US5595872A (en) | 1992-03-06 | 1997-01-21 | Bristol-Myers Squibb Company | Nucleic acids encoding microsomal trigyceride transfer protein |
US5712396A (en) | 1992-10-28 | 1998-01-27 | Magnin; David R. | α-phosphonosulfonate squalene synthetase inhibitors |
US5594016A (en) | 1992-12-28 | 1997-01-14 | Mitsubishi Chemical Corporation | Naphthalene derivatives |
EP0680320B1 (en) | 1993-01-19 | 1999-04-14 | Warner-Lambert Company | Stable oral ci-981 formulation and process of preparing same |
US5739135A (en) | 1993-09-03 | 1998-04-14 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
US5776983A (en) | 1993-12-21 | 1998-07-07 | Bristol-Myers Squibb Company | Catecholamine surrogates useful as β3 agonists |
US5488064A (en) | 1994-05-02 | 1996-01-30 | Bristol-Myers Squibb Company | Benzo 1,3 dioxole derivatives |
US5385929A (en) | 1994-05-04 | 1995-01-31 | Warner-Lambert Company | [(Hydroxyphenylamino) carbonyl] pyrroles |
US5612359A (en) | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
US5491134A (en) | 1994-09-16 | 1996-02-13 | Bristol-Myers Squibb Company | Sulfonic, phosphonic or phosphiniic acid β3 agonist derivatives |
US5541204A (en) | 1994-12-02 | 1996-07-30 | Bristol-Myers Squibb Company | Aryloxypropanolamine β 3 adrenergic agonists |
US5620997A (en) | 1995-05-31 | 1997-04-15 | Warner-Lambert Company | Isothiazolones |
AU6966696A (en) | 1995-10-05 | 1997-04-28 | Warner-Lambert Company | Method for treating and preventing inflammation and atherosclerosis |
ATE344279T1 (de) | 1995-12-13 | 2006-11-15 | Univ California | Kristalle der mit einem ligand komplexierten ligandenbindedomäne des schilddrüsenhormonrezeptors |
US5770615A (en) | 1996-04-04 | 1998-06-23 | Bristol-Myers Squibb Company | Catecholamine surrogates useful as β3 agonists |
US5962440A (en) | 1996-05-09 | 1999-10-05 | Bristol-Myers Squibb Company | Cyclic phosphonate ester inhibitors of microsomal triglyceride transfer protein and method |
US5827875A (en) | 1996-05-10 | 1998-10-27 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
US5885983A (en) | 1996-05-10 | 1999-03-23 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
US5760246A (en) | 1996-12-17 | 1998-06-02 | Biller; Scott A. | Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method |
TW536540B (en) | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
GB9713739D0 (en) | 1997-06-27 | 1997-09-03 | Karobio Ab | Thyroid receptor ligands |
EP1052994A2 (en) | 1998-02-02 | 2000-11-22 | Trustees Of Tufts College | Use of dipeptidylpetidase inhibitors to regulate glucose metabolism |
AU3034299A (en) | 1998-03-09 | 1999-09-27 | Fondatech Benelux N.V. | Serine peptidase modulators |
CN1203846C (zh) * | 1998-03-19 | 2005-06-01 | 布里斯托尔-迈尔斯斯奎布公司 | 高溶解性药物的双相控释递送***和方法 |
DE19823831A1 (de) | 1998-05-28 | 1999-12-02 | Probiodrug Ges Fuer Arzneim | Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen |
DE19828113A1 (de) | 1998-06-24 | 2000-01-05 | Probiodrug Ges Fuer Arzneim | Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV |
DE19828114A1 (de) | 1998-06-24 | 2000-01-27 | Probiodrug Ges Fuer Arzneim | Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV |
DE69940063D1 (de) | 1998-07-06 | 2009-01-22 | Bristol Myers Squibb Co | Biphenylsulfonamide als zweifach aktive rezeptor antagonisten von angiotensin und endothelin |
US6117451A (en) * | 1998-08-25 | 2000-09-12 | Pharmalogix, Inc. | Direct compression metformin hydrochloride tablets |
GB9828442D0 (en) | 1998-12-24 | 1999-02-17 | Karobio Ab | Novel thyroid receptor ligands and method II |
US6548529B1 (en) | 1999-04-05 | 2003-04-15 | Bristol-Myers Squibb Company | Heterocyclic containing biphenyl aP2 inhibitors and method |
US6414002B1 (en) | 1999-09-22 | 2002-07-02 | Bristol-Myers Squibb Company | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method |
TW200528436A (en) | 1999-09-22 | 2005-09-01 | Bristol Myers Squibb Co | Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method |
IL160917A0 (en) | 2001-10-18 | 2004-08-31 | Bristol Myers Squibb Co | Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions |
CN1700910A (zh) * | 2001-11-06 | 2005-11-23 | 兰贝克赛实验室有限公司 | 甲福明控释片剂 |
KR100897890B1 (ko) * | 2002-06-17 | 2009-05-18 | 인벤티아 헬스케어 피브이티. 엘티디. | 티아졸리딘디온 및 바이구아나이드를 함유하는 다층 정제및 그의 제조 방법 |
CA2494281A1 (en) * | 2002-08-02 | 2004-02-12 | Penwest Pharmaceuticals Company | Sustained release formulations of metformin |
DE10258007B4 (de) | 2002-12-12 | 2006-02-09 | Sanofi-Aventis Deutschland Gmbh | Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel |
EP1646374A1 (en) * | 2003-06-16 | 2006-04-19 | Ranbaxy Laboratories, Ltd. | Extended-release tablets of metformin |
DE102004028241B4 (de) | 2004-06-11 | 2007-09-13 | Sanofi-Aventis Deutschland Gmbh | Neue Fluorglykosidderivate von Pyrazolen, diese Verbindungen enthaltende Arzneimittel und Herstellung dieser Arzneimittel |
AR051446A1 (es) | 2004-09-23 | 2007-01-17 | Bristol Myers Squibb Co | Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2) |
EP1814528A2 (en) * | 2004-10-08 | 2007-08-08 | Rubicon Research Private Limited | Process for making a highly compressible controlled delivery compositions of metformin |
TW200726755A (en) | 2005-07-07 | 2007-07-16 | Astellas Pharma Inc | A crystalline choline salt of an azulene derivative |
US20080274180A1 (en) * | 2005-08-30 | 2008-11-06 | Nicholas Piramal India Limited | Extended Release Pharmaceutical Composition of Metformin and a Process for Producing It |
TWI370818B (en) | 2006-04-05 | 2012-08-21 | Astellas Pharma Inc | Cocrystal of c-glycoside derivative and l-proline |
EP2011808A1 (de) | 2007-07-03 | 2009-01-07 | Bayer MaterialScience AG | Medizinische Klebstoffe für die Chirurgie |
EP2183263B1 (en) | 2007-07-26 | 2011-10-26 | Lexicon Pharmaceuticals, Inc. | Methods and compounds useful for the preparation of sodium glucose co-transporter 2 inhibitors |
-
2010
- 2010-11-12 US US13/509,206 patent/US20120294936A1/en not_active Abandoned
- 2010-11-12 RU RU2012124239/15A patent/RU2564901C2/ru active
- 2010-11-12 CN CN2010800614094A patent/CN102711738A/zh active Pending
- 2010-11-12 CA CA2780938A patent/CA2780938A1/en not_active Abandoned
- 2010-11-12 MX MX2012005425A patent/MX2012005425A/es not_active Application Discontinuation
- 2010-11-12 EP EP10782112A patent/EP2498757A1/en not_active Withdrawn
- 2010-11-12 WO PCT/US2010/056525 patent/WO2011060255A1/en active Application Filing
- 2010-11-12 BR BR112012011274A patent/BR112012011274A2/pt not_active Application Discontinuation
- 2010-11-12 JP JP2012539016A patent/JP5798123B2/ja active Active
- 2010-11-12 AU AU2010319438A patent/AU2010319438B2/en active Active
-
2014
- 2014-05-06 US US14/270,854 patent/US20140335170A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2010319438A1 (en) | 2012-07-05 |
CN102711738A (zh) | 2012-10-03 |
US20140335170A1 (en) | 2014-11-13 |
CA2780938A1 (en) | 2011-05-19 |
JP5798123B2 (ja) | 2015-10-21 |
EP2498757A1 (en) | 2012-09-19 |
WO2011060255A1 (en) | 2011-05-19 |
RU2012124239A (ru) | 2013-12-20 |
AU2010319438B2 (en) | 2015-05-21 |
US20120294936A1 (en) | 2012-11-22 |
JP2013510872A (ja) | 2013-03-28 |
MX2012005425A (es) | 2012-06-14 |
RU2564901C2 (ru) | 2015-10-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112012011274A2 (pt) | formulação de metformina de massa reduzida e sua combinação | |
AR114143A2 (es) | Formulaciones de comprimidos revestidos | |
BR122016004010B8 (pt) | forma farmacêutica oral sólida de liberação prolongada | |
BRPI0606339A2 (pt) | formas farmacêuticas resistentes a álcool | |
BR112013022789A2 (pt) | composições farmacêuticas que compreendem metformina e um inibidor dpp-4 ou um inibidor sglt-2 | |
ECSP10010295A (es) | Formulacion de anticuerpo | |
GT200600347A (es) | Nueva formula cristalina iii de la agomelatina, su procedimiento de preparación y las composiciones farmacéuticas que la contienen | |
AR059194A1 (es) | Formas de dosificacion resistentes a la manipulacion | |
UY30319A1 (es) | Formulaciones de inhibidores de dpp iv | |
BRPI0913372A2 (pt) | ambiguidade de ponteiro múltiplo e resolução de oclusão. | |
CO6362017A2 (es) | Peptidos antivirales terapeuticos | |
NO20083895L (no) | Anti-IGF-1R human monoklonalantibody formulering | |
BRPI0814252A8 (pt) | composição farmacêutica aquosa compreendendo natalizumab | |
CR10157A (es) | Compuestos químicos | |
AR052925A1 (es) | Forma cristalina betad del clorhidrato de ivabradina, un procedimiento para su preparacion y composiciones farmaceuticas que la contienen | |
SV2008003088A (es) | Nueva forma cristalina vi de la agomelatina, su procedimiento de preparacion y las composiciones farmaceuticas que la contienen | |
ECSP11011307A (es) | Comprimidos para terapia de combinacion | |
EA201001402A1 (ru) | Фармацевтические растворы, способ получения и терапевтическое применение | |
UY30572A1 (es) | N-(1-ftalazin-1-il-piperidin-4-il)-amidas como moduladores del receptor ep2 | |
BRPI0908855A8 (pt) | Comestíveis revestidos e processos para sua preparação | |
BR112013025229A2 (pt) | medidor de fluxo | |
BR112014005935A2 (pt) | derivados de anilina, sua preparação e sua aplicação terapêutica | |
CR20150266A (es) | Formulaciones de liberación modificada para oprozomib | |
DE602006007855D1 (de) | Uhrwerk, das eine Halteplatte für einen Anzeigering umfasst | |
EA200900958A1 (ru) | Препарат невирапина пролонгированного высвобождения |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
B11E | Dismissal acc. art. 34 of ipl - requirements for examination incomplete | ||
B11T | Dismissal of application maintained [chapter 11.20 patent gazette] |